Oxaprotiline

Oxaprotiline (developmental code name CGP-6085), is a tricyclic antidepressant (TCA) that was developed in the late 1960s by Ciba, a Swiss multinational pharmaceutical company. It is a norepinephrine reuptake inhibitor with negligible effects on serotonin and dopamine reuptake.

Pharmacology

Oxaprotiline acts as a norepinephrine reuptake inhibitor and has negligible effects on the reuptake of serotonin and dopamine. It is also known to act as an antagonist of the histamine H1 receptor and alpha-1 adrenergic receptor, which may contribute to its side effect profile.

Clinical Use

Oxaprotiline is used in the treatment of depression. It has similar efficacy to other TCAs and selective serotonin reuptake inhibitors (SSRIs) in the treatment of depressive disorders.

Side Effects

Common side effects of oxaprotiline include dry mouth, constipation, blurred vision, and dizziness. Less common side effects can include tachycardia, hypotension, and urinary retention. As with other TCAs, oxaprotiline can also cause cardiotoxicity in overdose.

See Also

• Tricyclic antidepressant
• Norepinephrine reuptake inhibitor
• Histamine H1 receptor
• Alpha-1 adrenergic receptor

References

Oxaprotiline Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski